arXiv Science⌕ Search

arXiv subjects

Prajwal Ghimire

Publications and source records attributed to Prajwal Ghimire.

5 recordsLinked to original sources

Clinical predictions using artificial intelligence in neurosurgery and its subspecialties: a systematic review and meta-analysis

Artificial intelligence models for clinical prediction are proliferating across neurosurgery, but their aggregate discriminative performance, distribution along the care pathway and methodological quality are unclear. We systematically reviewed and meta-analysed these studies in neurosurgery and its subspecialities along with their risk of bias appraisal. We performed a PRISMA search for peer-reviewed original studies using AI to predict a clinical outcome in neurosurgical populations. Metrics were pooled using random effects modelling. Each study was classified as diagnostic, prognostic or forecasting and was assigned an evidence level. Clinical prediction task sub-stratification analysis was performed. Risk-of-bias was assessed using PROBAST. 1063 studies were included. Across 451 studies reporting AUC, pooled discrimination was 0.86, ranging from 0.84 (spine) to 0.87 (neuro-oncology), with extreme heterogeneity. Performance varied by clinical pathway stage, highest for diagnosis, grading and molecular tasks and lowest for post-operative tasks. Only 51 studies were using prospective data with external validation, whereas 619 rested on internal validation alone or no validation. 89 percent studies were at high risk-of-bias, driven by the analysis domain. AI models report high performance across all the neurosurgical subspecialities, concordant across AUC, accuracy, sensitivity and specificity and robust to risk-of-bias stratification. Performance is highest for imaging-anchored diagnostic tasks and lowest at decision-facing post-operative stage. However, the literature is dominated by optimism-prone, internally-validated and poorly calibrated models with extreme heterogeneity. External validation, calibration analysis and reporting guidelines adherence remain prerequisites for clinical adoption.

q-bio.TO↗

SurgTransfer: Multi-Step Latent Action Modeling for Action Transfer in Surgical World Model

Surgical world models have the potential to provide intra-operative guidance, accelerate risk-free training and facilitate transfer of expert surgical maneuvers. However, the use of world models for transferring surgical expertise has been largely unexplored. Moreover, recent approaches in this domain have mainly relied on ground truth kinematics actions or expert annotations for specific tasks, limiting their applicability beyond the narrow range of tasks with ground-truth annotations. In contrast, existing works in the natural domain have shown promising results in learning latent actions solely from unlabeled videos and transferring the learned actions across contexts. We observe that this paradigm is short-sighted for the surgical domain, failing to capture the hierarchical and goal-directed structure of surgical procedures. Thus, we propose a novel multi-step action learning framework to learn context-invariant latent actions that are easily transferable across various surgical contexts. We perform extensive experiments on the publicly available datasets, SurgToolLoc-2022 and PitVis-2023, verifying our approach with both quantitative metrics and qualitative evaluation by surgical experts. We have published our code and the implementation details at https://github.com/bhattarailab/Surgical-Vision-World-Model.

cs.CV↗

Predictive Radiomics for Evaluation of Cancer Immune SignaturE in Glioblastoma: the PRECISE-GBM study

Background: Radiogenomics allows identification of radiological biomarkers for genomic phenotypes. In glioblastoma, these biomarkers could potentially complement patient stratification strategies. We aim to develop and analytically validate radiological biomarkers that capture immune cell signatures within IDH-wildtype glioblastoma microenvironment using radiogenomic analysis. Methods: This was a retrospective multicenter study using curated open-access anonymized imaging and genomic data from TCGA-GBM, CPTAC, IvyGAP, REMBRANDT and CGGA datasets. Imaging data consisted of MRI-based radiomic features extracted from necrotic core, enhancing and edema regions of deep learning-based auto-segmented tumors. Radiomic feature selections were performed using nested cross-validated LASSO. Support vector machine and ensemble models were trained using seventeen immune and cell-specific score labels extracted from deconvoluted transcriptomic data using pan-cancer and glioblastoma immune signature matrices as reference standards. Seventeen classifier models trained in three cross-cohort strategies were validated on three held-out datasets assessing stability and generalizability. Results: One-hundred-and-seventy-six patients were included in the study. The immune-related radiomic signatures obtained after feature selection were shape, first order and higher order radiomic features. Models predicting macrophage subtype immune signature showed stable mean performance on balanced accuracy (0.67) and precision (0.89) metrics for three independent holdout datasets with ensemble model outperforming support vector machine model. Conclusion: Radiogenomic models non-invasively predicted the macrophage subtype M0 immune signature in IDH-wildtype glioblastoma. These biomarkers have the potential to stratify patients for immunotherapy within prospective glioblastoma clinical trials.

cs.LG↗

From artificial to organic: Rethinking the roots of intelligence for digital health

The term artificial implies an inherent dichotomy from the natural or organic. However, AI, as we know it, is a product of organic ingenuity: designed, implemented, and iteratively improved by human cognition. The very principles that underpin AI systems, from neural networks to decision-making algorithms, are inspired by the organic intelligence embedded in human neurobiology and evolutionary processes. The path from organic to artificial intelligence in digital health is neither mystical nor merely a matter of parameter count, it is fundamentally about organization and adaption. Thus, the boundaries between artificial and organic are far less distinct than the nomenclature suggests.

cs.AI↗

Radiogenomic biomarkers for immunotherapy in glioblastoma: A systematic review of magnetic resonance imaging studies

Immunotherapy is an effective precision medicine treatment for several cancers. Imaging signatures of the underlying genome (radiogenomics) in glioblastoma patients may serve as preoperative biomarkers of the tumor-host immune apparatus. Validated biomarkers would have the potential to stratify patients during immunotherapy clinical trials, and if trials are beneficial, facilitate personalized neo-adjuvant treatment. The increased use of whole genome sequencing data, and the advances in bioinformatics and machine learning make such developments plausible. We performed a systematic review to determine the extent of development and validation of immune-related radiogenomic biomarkers for glioblastoma. A systematic review was performed following PRISMA guidelines using the PubMed, Medline, and Embase databases. Qualitative analysis was performed by incorporating the QUADAS 2 tool and CLAIM checklist. PROSPERO registered CRD42022340968. Extracted data were insufficiently homogenous to perform a meta-analysis. Results Nine studies, all retrospective, were included. Biomarkers extracted from magnetic resonance imaging volumes of interest included apparent diffusion coefficient values, relative cerebral blood volume values, and image-derived features. These biomarkers correlated with genomic markers from tumor cells or immune cells or with patient survival. The majority of studies had a high risk of bias and applicability concerns regarding the index test performed. Radiogenomic immune biomarkers have the potential to provide early treatment options to patients with glioblastoma. Targeted immunotherapy, stratified by these biomarkers, has the potential to allow individualized neo-adjuvant precision treatment options in clinical trials. However, there are no prospective studies validating these biomarkers, and interpretation is limited due to study bias with little evidence of generalizability.

q-bio.TO↗